Showing 34,848 articles by Roger Pebody

Filters Author: Roger Pebody

Roger joined NAM in 2008 as an Editor and became Managing Editor in 2018. He is responsible for co-ordinating the editorial content of aidsmap.com, including news coverage and patient information materials. His involvement in HIV work began at Gay Men Fighting AIDS in the mid-1990s. Twitter: @RogerPebody

New & experimental HIV treatments

Broadly neutralising antibodies may be partners for long-acting antiretrovirals

News
6 March 2024
Pregnancy, children & young people

How Will We End Pediatric HIV? With More Options.

Editor's pick
TheBodyPro
6 March 2024
Resistance

New report documents increase in HIV drug resistance to dolutegravir

Editor's pick
World Health Organization
6 March 2024
Cardiovascular disease

Tools Underestimate Cardiovascular Event Risk in People with HIV

Editor's pick
National Institute of Allergy and Infectious Disease
6 March 2024
Discrimination & the law

IAS statement: Upsurge in anti-gay laws across Africa threatens the HIV response

Editor's pick
The International Aids Society
6 March 2024
Pregnancy and vertical transmission

Vaginal Ring and Oral Pre-Exposure Prophylaxis Found Safe for HIV Prevention Throughout Pregnancy

Editor's pick
National Institute of Allergy and Infectious Disease
6 March 2024

CROI 2024: Once-weekly antiretrovirals on the horizon, Wednesday 6 March 2024

March 2024
PrEP

HIV diagnoses continue to fall in US states with high PrEP coverage, while others are left behind

News
6 March 2024
New & experimental HIV treatments

Once-weekly antiretrovirals on the horizon

News
6 March 2024
New & experimental HIV treatments

If one antibody won’t work, how about three? Or three in one?

News
6 March 2024

КРОИ 2024: Заболеваемость ИППП в Сан-Франциско снизилась после развертывания программы доксициклиновой постконтактной профилактики «доксиПостКП». Вторник, 5 марта 2024 г.

March 2024
The search for a cure

Varying dolutegravir distribution across the body may affect the drug’s ability to suppress the HIV reservoir

News
5 March 2024

CROI 2024: San Francisco, IST in calo dopo l'introduzione della doxyPEP, martedì 5 marzo 2024

March 2024

CROI 2024 : Les cas d’IST ont chuté à San Francisco depuis l’extension de la doxyPEP, Mardi 5 mars 2024

March 2024

CROI 2024: As IST em São Francisco diminuíram desde o lançamento do doxyPEP, terça-feira, 5 de março de 2024

March 2024

CROI 2024: La tasa de ITS ha descendido en San Francisco desde la implementación de la doxyPEP. Martes, 5 de marzo de 2024

March 2024

CROI 2024: STIs in San Francisco have fallen since doxyPEP roll-out, Tuesday 5 March 2024

March 2024
PEP

People need pathways from PEP to PrEP – and back again

News
5 March 2024
Sexually transmitted infections prevention

Sexually transmitted infections in San Francisco have fallen since doxyPEP roll-out

News
5 March 2024
Sexually transmitted infections prevention

Full analysis of French STI study dashes hopes for a gonorrhoea vaccine

News
4 March 2024
Injectable & long-acting HIV treatment

Injectable treatment just as effective as standard HIV combination in Africa

News
4 March 2024
PrEP

Factors Influencing PrEP Uptake Among Black MSM, Transgender Women

Editor's pick
Physician's Weekly
4 March 2024
Injectable & long-acting HIV treatment

Just as CROI Gets Ready to Start, an Important Change to the IAS-USA HIV Treatment Guidelines

Editor's pick
HIV and ID Observations
3 March 2024
Human rights

Ghana’s Parliament Passes Draconian Law With Prison Terms for People Who ‘Identify” as LGBTIQ

Editor's pick
Health Policy Watch
2 March 2024